Long-term Safety Study of Pelacarsen Treatment
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study follows patients who completed an earlier pelacarsen trial to check if the treatment remains safe and well-tolerated over time. Pelacarsen is an experimental medicine being tested for heart and cholesterol health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the parent study (CTQJ230A12301) and were still taking the study drug at the end
- You did not permanently stop or pause the study drug for 6 months or longer before the parent study ended
- You are not currently taking another experimental drug or device
- You do not have a known allergy or sensitivity to pelacarsen
- You have no serious medical conditions that would make the study unsafe for you
- You are willing to provide informed consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who have already finished taking pelacarsen in a previous study. It offers continued access to the drug and checks long-term safety.
This program provides access to pelacarsen (TQJ230) for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer potential benefit when standard therapies are not suitable.
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This study tests whether pelacarsen, an experimental medicine, can safely lower Lp(a)—a type of cholesterol linked to heart disease—in people who recently had a heart attack. The goal is to see if lowering Lp(a) can help prevent future heart problems.
This study tests an oral medicine (HRS-5346) to lower lipoprotein(a), a type of fat in the blood linked to heart problems. It might help people with high levels who are at increased risk for heart attacks or strokes.
Hear when a new Cardiovascular Disease and Lipoprotein(a) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.